Sold as Darvon-N. Every FDA application for this active ingredient.
As of Nov 15, 2026, FDA lists 2 applications for Propoxyphene Napsylate (sold as Darvon-N), first approved Sep 9, 1971, with 0 new uses approved and 0 published complete response letters.
| Sep 9, 1971 | Darvon-NNDA 16861 · New dosage form | Aaipharma LLC | 13 | Discontinued |
| Sep 9, 1971 | Darvon-NNDA 16862 · New dosage form | Xanodyne Pharm | 26 | Discontinued |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
